{"id":"W3135441040","doi":"10.1200/jco.2021.39.6_suppl.tps190","title":"A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Exelixis","keywords":"Cabozantinib; Medicine; Atezolizumab; Prostate cancer; Oncology; Internal medicine; Cancer; Enzalutamide; Nivolumab; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002158782,0.002416485,0.002616797,0.0005638003,0.0005840618,0.001401615,0.001407816,0.002324904,0.006924833],"category_scores_gemma":[0.001843918,0.0008601713,0.002109994,0.0005967896,0.001718074,0.001403932,0.0004762634,0.004020788,0.001389076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001352744,"about_ca_system_score_gemma":0.002255814,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001793928,"about_ca_topic_score_gemma":0.004491241,"domain_scores_codex":[0.9991632,0.0004748133,0.00003634479,0.0001398222,0.00005743568,0.0001284358],"domain_scores_gemma":[0.998437,0.0003705356,0.0003148726,0.0001297027,0.00008644492,0.0006615266],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.963175,0.01931527,0.001405308,0.0002803419,0.0006390337,0.00007775243,0.00008982084,0.0004464681,0.004696217,0.00009025833,0.0008458666,0.008938585],"study_design_scores_gemma":[0.8984939,0.09858236,0.001581211,0.000007522142,0.0001758823,0.00005250843,0.0000209393,0.0002555437,0.0003411744,0.00008449757,0.0003939998,0.00001044239],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872069,0.001247408,0.0006744847,0.0006511619,0.0003625922,0.005876036,0.001801821,0.0001587296,0.002020896],"genre_scores_gemma":[0.9816781,0.001065441,0.00217927,0.001868255,0.0005481436,0.006847154,0.002608947,0.00004782172,0.003156839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006924833,"threshold_uncertainty_score":0.02316588,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1954884898162561,"score_gpt":0.4756110529767282,"score_spread":0.280122563160472,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}